Mountain View, CA, April 5, 2005
IMPAC Medical Systems,
Inc., part of the Elekta Group and a leading provider of
information technology solutions for oncology care, and Synovate
Healthcare, a specialist division of global research firm
Synovate, will align to supplement Synovate's global cancer
therapy audit with longitudinal oncology data that will enhance
Synovate’s current offerings and allow creation of new services
and insight into the market. In this multi-year agreement,
Synovate will license aggregated and de-identified data
collected from users of IMPAC’s leading oncology EMR and cancer registry
systems. This will enable Synovate to provide timely and
accurate, de-identified information to pharmaceutical and
biotech companies in an effort to further oncology research.
“This alliance will enable us to expand our current data
collection methods from paper to electronic – exponentially
impacting the speed of oncology data collected and
allowing us to better analyze, understand, and extrapolate
trends and outcomes in oncology care,” stated Michael Spedding,
CEO of Synovate Healthcare.
“IMPAC’s goal from the beginning has been to promote healthcare
technology to deliver practical solutions that will improve
overall communication, process efficiency, and the quality of
patient care,” added Joseph K. Jachinowski, president and CEO of
IMPAC Medical Systems. “Sharing the longitudinal data collected
from the National Oncology Database™ (NODB) solidifies our goals
and achievements over our 15 year history. This is a significant
development in market research that ultimately will be
demonstrated with improved patient care.”
This agreement represents a considerable step forward in market
research through the quantity and quality of longitudinal data
to be shared and analyzed. Synovate will gain access to the
electronic data of more than 2.3 million cases resident in the
IMPAC NODB and augmented by IMPAC software products and services
which span the spectrum of cancer care.
********For more
information, please contact:
Julie DeSantis, Public Relations Manager
IMPAC Medical Systems, Inc.
Tel: +1 650-623-8883, e-mail: pr@impac.com
Investor Enquiries:
International: Peter Ejemyr, Group VP Corporate Communications,
Elekta AB
Tel: +46 733 611 000, e-mail: peter.ejemyr@elekta.com
United States: Lars Jonsteg, VP Investor Relations North
America, Elekta Inc.
Tel: +46 708-783 735, e-mail:
lars.jonsteg@elekta.com
About IMPAC Medical Systems
IMPAC Medical Systems, Inc., a wholly owned
subsidiary of Elekta AB, is a leading provider of oncology IT
solutions that streamline both clinical and business operations to
help improve the process of delivering quality patient care. With
systems designed for anatomic pathology, medical oncology,
radiation oncology, imaging, clinical laboratory, and cancer
registry, IMPAC supports the entire team of healthcare
professionals who contribute to the care of the cancer patient.
Supporting more than 2500 installations worldwide, IMPAC provides
practical solutions that deliver better overall communication,
process efficiency and quality patient care. For more information
about IMPAC’s products or services, please call 888-GO-IMPAC or
visit www.impac.com.
The Elekta Group is a world-leading supplier of advanced and
innovative radiation oncology and neurosurgery solutions and
services for precise treatment of cancer and brain disorders.
About
Synovate Healthcare
Synovate, the market research arm of Aegis Group plc, generates
consumer insights that drive competitive market solutions. The
network provides clients cohesive global support and a
comprehensive suite of research solutions. Synovate employs over
4000 staff in 44 countries. More information can be found at
www.synovate.com. |
